GlaxoSmithKline LLC v. Teva Pharmnaceuticals USA (Fed. Cir. 2022)
Federal Circuit Denies En Banc Review in GlaxoSmithKline LLC v. Teva Pharmaceuticals USA By Kevin E. Noonan — The 2020 decision by a divided Federal […]
Federal Circuit Denies En Banc Review in GlaxoSmithKline LLC v. Teva Pharmaceuticals USA By Kevin E. Noonan — The 2020 decision by a divided Federal […]
By Kevin E. Noonan — The question of the proper court for a branded pharmaceutical maker to bring suit against an Abbreviated New Drug Application […]
By Kevin E. Noonan — The question of the proper court for a branded pharmaceutical maker to bring suit against an Abbreviated New Drug Application […]
By Kevin E. Noonan — The Federal Trade Commission (FTC) spent the better part of a decade attacking the practice of innovator drug companies settling […]
By Kevin E. Noonan — ANDA litigation, pursuant to the Hatch-Waxman Act, has become more complicated over the years since enactment of the statute in […]
Copyright © 2024 | WordPress Theme by MH Themes